What Privigen contains
The active substance is human normal immunoglobulin antibodies of the type IgG. Privigen contains 100 mgml 10 human protein of which at least 98 is IgG. The other ingredients are the amino acid L-proline and water for injections.
What Privigen looks like and contents of the pack
Privigen is presented as a solution for infusion.
The solution is clear or slightly opalescent and colourless to pale-yellow.
Pack sizes:
1 vial (2.5 g/25 ml, 5 g/50 ml, 10 g/100 ml or 20 g/200 ml),
3 vials (10 g/100 ml or 20 g/200 ml).
Not all pack sizes may be marketed.
Marketing Authorisation Holder and Manufacturer
CSL Behring GmbH
Emil-von-Behring-Strasse 76
D-35041 Marburg
Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
BelgiëBelgiqueBelgien CSL Behring NV Technologielaan 13 B-3001 Leuven TélTel 32 16 38 80 80 LuxembourgLuxemburg CSL Behring NV Technologielaan 13 B-3001 Leuven, BelgiqueBelgien TélTel 32 16 38 80 80
114, 1404, , 359 2 958 84 68 Magyarország Plazmed Kft. F u. 200 H-2193 Galgahévíz Tel. 36 28 59 10 00
eská republika IBP medica s.r.o. Pod Karlovem 81670 CZ 120 00 Praha 2 Tel 42 02 22 56 07 23 Malta AM Mangion Ltd. Mangion Buildings New Street in Valletta Road MT-LQA 6000 Luqa Tel 356 2397 6333
Danmark CSL Behring ApS Lyngby Hovedgade 70B, 1.tv DK-2800 Kgs. Lyngby Tlf 45 4520 1420 Nederland CSL Behring BV Claudius Prinsenlaan 128 NL-4818 CP Breda Tel 31 76 523 6045
Deutschland CSL Behring GmbH Philipp-Reis-Strasse 2 D-65795 Hattersheim Tel 49 69 30584437 Norge CSL Behring AB P.O.Box 712 S-182 17 Danderyd, Sverige Tlf 46 8 544 966 70
Eesti CSL Behring AB P.O.Box 712 S-182 17 Danderyd, Rootsi Tel 46 8 544 966 70 Österreich CSL Behring GmbH Altmannsdorfer Strasse 104 A-1121 Wien Tel 43 1 80101 2463
CSL Behring 5 GR-115 28 30 210 7255 660 Polska Imed Poland sp. z.o.o. Ul. Puawska 314 PL-02-819 Warszawa Tel. 48 22 663 43 10
España CSL Behring S.A. Av. Països Catalans, 34, 3aE-08950 Esplugues de Llobregat Barcelona Tel 34 933 67 1870 Portugal CSL Behring Lda Av. 5 de Outubro, 198 3 Esq. P-1050-064 Lisboa Tel 351 21 782 62 30
France CSL Behring SA 30 rue Cambronne F-75015 Paris Tél 33 1 53 58 54 00 România Nicofarma DCI SRL Strada Tepe Voda 79 Sector 2 Bucureti 021522-RO Tel 40 21 327 2614
Slovenija MediSanus d.o.o. Vagajeva ulica 4 SI-1000 Ljubljana Tel 386 1 25 71 496 Ireland CSL Behring UK Ltd. Hayworth House, Market Place Haywards Heath, West Sussex RH16 1DB UK Tel 44 1444 447400
Ísland CSL Behring AB P.O.Box 712 S-182 17 Danderyd, Svíjóð Sími 46 8 544 966 70 Slovenská republika TIMED, s.r.o. Trnavská cesta 112 SK-821 01 Bratislava Tel 421 2 4820 95 11
Italia CSL Behring S.p.A. Viale Del Ghisallo, 20 I-20151 Milano Tel 39 02 34964 200 SuomiFinland CSL Behring AB P.O.Box 712 S-182 17 Danderyd, RuotsiSverige PuhTel 46 8 544 966 70
. 4 CY-1522 357 22677038 Sverige CSL Behring AB P.O.Box 712 S-182 17 Danderyd Tel 46 8 544 966 70
Latvija CSL Behring AB P.O.Box 712 S-182 17 Danderyd, Zviedrija Tel 46 8 544 966 70 United Kingdom CSL Behring UK Ltd. Hayworth House, Market Place Haywards Heath, West Sussex RH16 1DB UK Tel 44 1444 447400
Lietuva
CSL Behring AB
P.O.Box 712
S-182 17 Danderyd, ?vedija
Tel: +46 8 544 966 70
This leaflet was last approved in
-------------------------------------------------------------------------------------------------------------------------- The following information is intended for healthcare professionals only:
Posology and method of administration
The dosage recommendations are summarised in the following table:
Dose Frequency of injections Indication Replacement therapy in primary immunodeficiency starting dose 0.40.8 gkg bw thereafter 0.20.8 gkg bw every two to four weeks to obtain IgG trough levels of at least 46 gl in secondary immunodeficiency 0.20.4 gkg bw every three to four weeks to obtain IgG trough levels of at least 46 gl Children with AIDS 0.20.4 gkg bw every three to four weeks Immunomodulation Immune thrombocytopenic purpura 0.81 gkg bw on day one, possibly repeated once within three days or 0.4 gkg bwd for two to five days Guillain-Barré syndrome 0.4 gkg bwd for three to seven days Kawasaki disease 1.62 gkg bw in divided doses over two to five days in association with acetylsalicylic acid or 2 gkg bw in one dose in association with acetylsalicylic acid Allogeneic bone marrow transplantation 0.5 gkg bw treatment of infections and prophylaxis of graft versus host disease every week from seven days before up to three months after transplantation persistent lack of antibody production 0.5 gkg bw every month until antibody levels return to normal
Method of administration
- Human normal immunoglobulin should be infused intravenously. The initial infusion rate is 0.3 ml/kg bw/hr. If well tolerated, the rate of administration may gradually be increased to 4.8 ml/kg bw/hr.
- In PID patients who have tolerated the infusion rate of 4.8 ml/kg bw/hr well, the rate may be further increased gradually to a maximum of 7.2 ml/kg bw/hr.
- If dilution prior to infusion is desired, Privigen may be diluted with 5% glucose solution to a final concentration of 50 mg/ml (5%). Special precautions
- In case of adverse reaction, either the rate of administration must be reduced or the infusion stopped.
- It is strongly recommended that every time Privigen is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
Incompatibilities
This medicinal product must not be mixed with other medicinal products
Special precautions for disposal and other handling
- The product should be at room or body temperature before use. A vented infusion line should be used for the administration of Privigen. Always pierce the stopper at its centre, within the marked area.
- The solution should be clear or slightly opalescent. Do not use solutions that are cloudy or have particulate matter.
- If dilution is desired, 5% glucose solution is recommended. For obtaining an immunoglobulin solution of 50 mg/ml (5%), Privigen 100mg/ml (10%) should be diluted with an equal volume of the glucose solution. Aseptic technique must be strictly observed during the dilution of Privigen.
- Once the vial has been entered under aseptic conditions, its contents should be used promptly. Because the solution contains no preservative, Privigen should be infused as soon as possible.
- Any unused product or waste material should be disposed of in accordance with local requirements.